<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850601</url>
  </required_header>
  <id_info>
    <org_study_id>2016D003018</org_study_id>
    <nct_id>NCT02850601</nct_id>
  </id_info>
  <brief_title>Dexamethasone Solution for the Treatment of Oral Lichen Planus</brief_title>
  <official_title>Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Lichen Planus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this single center, 4-week, open label randomized, phase II study is to&#xD;
      evaluate and characterize the tolerability and clinical effectiveness of dexamethasone&#xD;
      0.5mg/5ml solution in a mucoadhesive vehicle (Mucolox™) for the treatment of oral lichen&#xD;
      planus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potentially eligible subjects will be screened by one of the investigators by asking patients&#xD;
      to rate their worst oral pain or pain score (0-10) over the previous week (see Appendix).&#xD;
      Those answering with at least a score of &quot;7&quot; (1/10) and that meet all other eligibility&#xD;
      requirements (see Section 3) will be eligible for enrollment. All patients will sign informed&#xD;
      consent for study participation. Each study visit is anticipated to take approximately 45&#xD;
      minutes.&#xD;
&#xD;
      Treatment will be administered on an outpatient basis. Study medication will be prescribed by&#xD;
      authorized study staff physicians at no expense for the patient.&#xD;
&#xD;
      Subjects will be evaluated clinically at baseline before starting treatment and at the end of&#xD;
      the four-week period, for a total of two visits. Comprehensive subjective and objective data&#xD;
      will be collected and intraoral photographs will be obtained. Oral mucosal disease will be&#xD;
      evaluated using both patient reported (questions/visual analog scales) and clinician assessed&#xD;
      measures.&#xD;
&#xD;
      Subjects will be prescribed compound dexamethasone 0.5mg/5ml solution in Mucolox™ (ARM A) or&#xD;
      dexamethasone 0.5mg/5ml solution only (ARM B). All subjects will also receive a prescription&#xD;
      for fluconazole 200 mg tablets once-a-week as prophylactic antifungal therapy. Any subjects&#xD;
      that are already taking an antifungal oral medication at the time of the study enrollment&#xD;
      will continue their prescribed medication and will not need to take the additional weekly&#xD;
      fluconazole dose. Subjects will return for evaluation after four weeks at which time the&#xD;
      study end-points will be assessed.&#xD;
&#xD;
      If there is worsening of oral lichen planus that requires initiation of new immunomodulatory&#xD;
      medications (systemic or topical), patients will remain on treatment, but will be regarded as&#xD;
      unevaluable for the primary endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2017</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Oral Sensitivity</measure>
    <time_frame>4 weeks after the start of the trial</time_frame>
    <description>Subjects scored their worse sensitivity while eating over the past week. This score is substracted from their initial reported sensitivity at baseline.&#xD;
Reduction in oral symptoms of the worst sensitivity experienced in the past week on an 11 point scale (visual analogue scale 0-10). O signifies no sensitivity; 10 maximum sensitivity substracted from the same score collected at baseline before the treatment was initiated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Dexamethasone solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone solution in Mucolox™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate</description>
    <arm_group_label>Dexamethasone solution</arm_group_label>
    <arm_group_label>Dexamethasone solution in Mucolox™</arm_group_label>
    <other_name>Decadron Elixir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older.&#xD;
&#xD;
          -  Patients with symptomatic oral lichen planus (worst VAS sensitivity score ≥ 7 over the&#xD;
             last week).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients already on topical or systemic steroids.&#xD;
&#xD;
          -  Inability to comply with study instructions.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  VAS sensitivity score &lt; 7.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <results_first_submitted>February 26, 2021</results_first_submitted>
  <results_first_submitted_qc>April 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2021</results_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Herve Y. Sroussi, D.M.D.,Ph.D.</investigator_full_name>
    <investigator_title>Oral Medicine Attending</investigator_title>
  </responsible_party>
  <keyword>Oral lichen planus</keyword>
  <keyword>Dexamethasone solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02850601/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone Solution</title>
          <description>Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks&#xD;
Dexamethasone: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone Solution in Mucolox™</title>
          <description>Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks&#xD;
Dexamethasone: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone Solution</title>
          <description>Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks&#xD;
Dexamethasone: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone Solution in Mucolox™</title>
          <description>Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks&#xD;
Dexamethasone: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.2" lower_limit="74" upper_limit="84"/>
                    <measurement group_id="B2" value="58.8" lower_limit="45" upper_limit="80"/>
                    <measurement group_id="B3" value="69.5" lower_limit="45" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sensitivity at baseline on a 0-10 scale</title>
          <description>Subjects scored their worse sensitivity while eating over the past week on an 11 point scale (visual analogue scale 0-10). O signifies no sensitivity; 10 maximum sensitivity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="B2" value="8" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="B3" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Oral Sensitivity</title>
        <description>Subjects scored their worse sensitivity while eating over the past week. This score is substracted from their initial reported sensitivity at baseline.&#xD;
Reduction in oral symptoms of the worst sensitivity experienced in the past week on an 11 point scale (visual analogue scale 0-10). O signifies no sensitivity; 10 maximum sensitivity substracted from the same score collected at baseline before the treatment was initiated.</description>
        <time_frame>4 weeks after the start of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone Rinses</title>
            <description>12 subjects A four-week supply of dexamethasone solution (0.1mg/ml) was dispensed and subjects were instructed to swish for 5 minutes and expectorate with 5 mL of solution, three times a day, and to avoid eating or drinking for 15 minutes</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone in Mucolox Rinses</title>
            <description>12 subjects A four-week supply of dexamethasone in Mucolox at 0.1mg/ml was dispensed and subjects were instructed to swish for 5 minutes and expectorate with 5 mL of solution, three times a day, and to avoid eating or drinking for 15 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oral Sensitivity</title>
          <description>Subjects scored their worse sensitivity while eating over the past week. This score is substracted from their initial reported sensitivity at baseline.&#xD;
Reduction in oral symptoms of the worst sensitivity experienced in the past week on an 11 point scale (visual analogue scale 0-10). O signifies no sensitivity; 10 maximum sensitivity substracted from the same score collected at baseline before the treatment was initiated.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="2.5"/>
                    <measurement group_id="O2" value="-6.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Onset of symptoms were reported 4-5 days after initiating the treatment and lasted 24h. The treatment was interrupted for 2 days and resumed thereafter with no recurrence or any other adverse event. The subject was monitored through study completion (4 weeks after baseline).</time_frame>
      <desc>Abdominal discomfort 4-5 days after initiating study drug. Study drug was discontinued and event ended 2 days later and did not recur.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone Solution</title>
          <description>Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks&#xD;
Dexamethasone: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone Solution in Mucolox™</title>
          <description>Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks&#xD;
Dexamethasone: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation; abdomional discomfort</sub_title>
                <description>Stopped study meds and recovered after 1 day</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Herve Sroussi</name_or_title>
      <organization>BWH</organization>
      <phone>617 5256864</phone>
      <email>hsroussi@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

